A
ALTO NEUROSCIENCE, INC.
NYSE: ANRO (Alto Neuroscience, Inc.)
Last update: yesterday, 9:59PM2.41
-0.04 (-1.63%)
| Previous Close | 2.45 |
| Open | 2.43 |
| Volume | 152,077 |
| Avg. Volume (3M) | 253,239 |
| Market Cap | 65,243,764 |
| Price / Book | 0.470 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Diluted EPS (TTM) | -2.30 |
| Total Debt/Equity (MRQ) | 19.01% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -53.00 M |
| Levered Free Cash Flow (TTM) | -39.36 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Alto Neuroscience, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.0
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.00 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.48% |
| % Held by Institutions | 77.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alpha Wave Global, Lp | 31 Mar 2025 | 3,707,757 |
| Vestal Point Capital, Lp | 31 Mar 2025 | 915,000 |
| Awm Investment Company, Inc. | 31 Mar 2025 | 901,984 |
| 72 Investment Holdings, Llc | 31 Mar 2025 | 667,778 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 314.94%) | Buy |
| Median | 7.00 (190.46%) | |
| Low | 4.00 (Wedbush, 65.98%) | Hold |
| Average | 7.00 (190.46%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 2.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 15 May 2025 | 4.00 (65.98%) | Hold | 2.43 |
| HC Wainwright & Co. | 07 Apr 2025 | 10.00 (314.94%) | Buy | 2.26 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |